Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


01.04.2019

1 AJR Am J Roentgenol
1 Am J Gastroenterol
2 Biochem Biophys Res Commun
4 BMC Cancer
1 Cancer Res
3 Dig Dis Sci
1 Endoscopy
3 Eur Radiol
2 Gastroenterology
1 Gut
9 Hepatology
2 J Gastroenterol
2 J Gastroenterol Hepatol
2 J Hepatol
2 Lancet
1 Lancet Gastroenterol Hepatol
1 PLoS Med
4 PLoS One
5 Semin Liver Dis
2 Transplant Proc


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. POOLER BD, Hernando D, Reeder SB
    Clinical Implementation of a Focused MRI Protocol for Hepatic Fat and Iron Quantification.
    AJR Am J Roentgenol. 2019 Mar 27:1-6. doi: 10.2214/AJR.18.20947.
    PubMed     Text format     Abstract available


    Am J Gastroenterol

  2. KLOMPENHOUWER AJ, Alblas M, Vivica van Rosmalen B, Haring MPD, et al
    Development and Validation of a Model to Predict Regression of Large Size Hepatocellular Adenoma.
    Am J Gastroenterol. 2019 Mar 27. doi: 10.14309/ajg.0000000000000182.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  3. MONTEFUSCO DJ, Allegood JC, Spiegel S, Cowart LA, et al
    Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
    Biochem Biophys Res Commun. 2018;504:608-616.
    PubMed     Text format     Abstract available

  4. WANG J, Wang Z, Sun Y, Liu D, et al
    Bryostatin-1 inhibits cell proliferation of hepatocarcinoma and induces cell cycle arrest by activation of GSK3beta.
    Biochem Biophys Res Commun. 2019 Mar 20. pii: S0006-291X(19)30385.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. HE L, Deng H, Lei J, Yi F, et al
    Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.
    BMC Cancer. 2019;19:276.
    PubMed     Text format     Abstract available

  6. SINN DH, Kang D, Kang M, Paik SW, et al
    Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study.
    BMC Cancer. 2019;19:286.
    PubMed     Text format     Abstract available

  7. FAN Y, Li S, Ding X, Yue J, et al
    First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
    BMC Cancer. 2019;19:279.
    PubMed     Text format     Abstract available

  8. CHEN LC, Chiou WY, Lin HY, Lee MS, et al
    Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.
    BMC Cancer. 2019;19:275.
    PubMed     Text format     Abstract available


    Cancer Res

  9. SUN F, Wang Y, Luo X, Ma Z, et al
    Anti-CD24 antibody-nitric oxide conjugate (ANC) selectively and potently suppresses hepatic carcinoma.
    Cancer Res. 2019 Mar 27. pii: 0008-5472.CAN-18-2839.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  10. XI L, Zhu J, Zhang H, Muktiali M, et al
    Epidemiological Trends in Gastrointestinal Cancers in China: An Ecological Study.
    Dig Dis Sci. 2019;64:532-543.
    PubMed     Text format     Abstract available

  11. ZHAO J, Xu H, Li Y, Gong L, et al
    NAFLD Induction Delays Postoperative Liver Regeneration of ALPPS in Rats.
    Dig Dis Sci. 2019;64:456-468.
    PubMed     Text format     Abstract available

  12. KOHLI R, Shingina A, New S, Chaturvedi S, et al
    Thromboelastography Parameters Are Associated with Cirrhosis Severity.
    Dig Dis Sci. 2019 Mar 26. pii: 10.1007/s10620-019-05597.
    PubMed     Text format     Abstract available


    Endoscopy

  13. SPORTES A, Leblanc S, Bordacahar B, Barret M, et al
    Peroral intraductal cholangioscopy-guided laser lithotripsy via endoscopic ultrasound-guided hepaticogastrostomy for intrahepatic bile duct lithiasis.
    Endoscopy. 2019 Mar 25. doi: 10.1055/a-0866-8986.
    PubMed     Text format    


    Eur Radiol

  14. JI GW, Zhu FP, Zhang YD, Liu XS, et al
    A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma.
    Eur Radiol. 2019 Mar 26. pii: 10.1007/s00330-019-06142.
    PubMed     Text format     Abstract available

  15. YOSHIMITSU K
    Differentiation of two subtypes of intrahepatic cholangiocarcinoma: imaging approach.
    Eur Radiol. 2019 Mar 26. pii: 10.1007/s00330-019-06135.
    PubMed     Text format     Abstract available

  16. ZHENG W, Zhou ZG, Wong CH, Pei XQ, et al
    Evaluation of liver parenchyma stiffness in patients with liver tumours: optimal strategy for shear wave elastography.
    Eur Radiol. 2019;29:1479-1488.
    PubMed     Text format     Abstract available


    Gastroenterology

  17. MOON AM, Weiss NS, Beste LA, Su F, et al
    Reply.
    Gastroenterology. 2019;156:1218-1220.
    PubMed     Text format    

  18. FERNANDEZ J, Claria J, Amoros A, Aguilar F, et al
    Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis.
    Gastroenterology. 2019 Mar 21. pii: S0016-5085(19)33576.
    PubMed     Text format     Abstract available


    Gut

  19. ZHU Y, Yang J, Xu D, Gao XM, et al
    Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Gut. 2019 Mar 22. pii: gutjnl-2019-318419. doi: 10.1136/gutjnl-2019-318419.
    PubMed     Text format     Abstract available


    Hepatology

  20. ELKRIEF L, Ferrusquia-Acosta J, Payance A, Moga L, et al
    Abdominal surgery in patients with idiopathic noncirrhotic portal hypertension: a multicenter retrospective study.
    Hepatology. 2019 Mar 29. doi: 10.1002/hep.30628.
    PubMed     Text format     Abstract available

  21. NAIR KM, Vora RS, Mousa OY, Malhi H, et al
    Hepatology Highlights.
    Hepatology. 2019;69:1365-1368.
    PubMed     Text format    

  22. RUSSELL BE, Whaley KG, Bove KE, Labilloy A, et al
    Expanding and Underscoring the Hepato-Encephalopathic Phenotype of QIL1/MIC13.
    Hepatology. 2019 Mar 26. doi: 10.1002/hep.30627.
    PubMed     Text format     Abstract available

  23. YANG J, Trepo E, Nahon P, Cao Q, et al
    A HSD17B13 variant protects from hepatocellular carcinoma development in alcoholic liver disease.
    Hepatology. 2019 Mar 25. doi: 10.1002/hep.30623.
    PubMed     Text format     Abstract available

  24. KIM G, Lee SE, Lee YB, Jun JE, et al
    Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study.
    Hepatology. 2018;68:1755-1768.
    PubMed     Text format     Abstract available

  25. YU CJ, Wang QS, Wu MM, Song BL, et al
    TRUSS Exacerbates NAFLD Development by Promoting IkappaBalpha Degradation in Mice.
    Hepatology. 2018;68:1769-1785.
    PubMed     Text format     Abstract available

  26. WU R, Murali R, Kabe Y, French SW, et al
    Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition.
    Hepatology. 2018;68:1726-1740.
    PubMed     Text format     Abstract available

  27. KLINGENBERG M, Gross M, Goyal A, Polycarpou-Schwarz M, et al
    The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling.
    Hepatology. 2018;68:1817-1832.
    PubMed     Text format     Abstract available

  28. TUFONI M, Serena Ricci C, Zaccherini G
    A Case of Immune-Mediated Liver Injury Induced by Olaparib.
    Hepatology. 2018;68:2039-2041.
    PubMed     Text format    


    J Gastroenterol

  29. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Response to the letter by Sumida et al. regarding our manuscript "Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease".
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01574.
    PubMed     Text format    

  30. SUMIDA Y, Yoneda M, Okanoue T
    Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01573.
    PubMed     Text format    


    J Gastroenterol Hepatol

  31. DE JONGE P, de Man RA, van Buuren HR
    Gastrointestinal: Rare cause of hematemesis initially presenting as a bleeding gastric Dieulafoy's lesion.
    J Gastroenterol Hepatol. 2018;33:6.
    PubMed     Text format    

  32. CHITTURI S, Wong VW, Chan WK, Wong GL, et al
    The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.
    J Gastroenterol Hepatol. 2018;33:86-98.
    PubMed     Text format    


    J Hepatol

  33. ZHANG X, Fan L, Wu J, Xu H, et al
    Macrophage p38alpha promotes nutritional steatohepatitis through M1 polarization.
    J Hepatol. 2019 Mar 23. pii: S0168-8278(19)30184.
    PubMed     Text format     Abstract available

  34. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Mar 22. pii: S0168-8278(19)30183.
    PubMed     Text format     Abstract available


    Lancet

  35. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet. 2019 Mar 22. pii: S0140-6736(18)31875.
    PubMed     Text format     Abstract available

  36. LEVY S, Samuel D
    Prevention of decompensation in cirrhosis: a new youth for beta blockers.
    Lancet. 2019 Mar 22. pii: S0140-6736(19)30736.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  37. THE LANCET GASTROENTEROLOGY HE
    Drinking to death: the changing face of liver disease.
    Lancet Gastroenterol Hepatol. 2018;3:655.
    PubMed     Text format    


    PLoS Med

  38. SNOWDON VK, Lachlan NJ, Hoy AM, Hadoke PW, et al
    Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.
    PLoS Med. 2017;14:e1002248.
    PubMed     Text format     Abstract available


    PLoS One

  39. BHAGAT HA, Compton SA, Musso DL, Laudeman CP, et al
    N-substituted phenylbenzamides of the niclosamide chemotype attenuate obesity related changes in high fat diet fed mice.
    PLoS One. 2018;13:e0204605.
    PubMed     Text format     Abstract available

  40. LEE SH, Park M, Park KM, Gwag HB, et al
    Corrected QT interval on the electrocardiogram after liver transplantation: Surrogate marker of poor clinical outcomes?
    PLoS One. 2018;13:e0206463.
    PubMed     Text format     Abstract available

  41. PETTINELLI P, Arendt BM, Teterina A, McGilvray I, et al
    Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0205747.
    PubMed     Text format     Abstract available

  42. FAROUK S, Sabet S, Abu Zahra FA, El-Ghor AA, et al
    Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis.
    PLoS One. 2018;13:e0206130.
    PubMed     Text format     Abstract available


    Semin Liver Dis

  43. FUJIWARA N, Hoshida Y
    Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis.
    Semin Liver Dis. 2019 Mar 25. doi: 10.1055/s-0039-1681031.
    PubMed     Text format     Abstract available

  44. KIM G, Kang ES
    Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms.
    Semin Liver Dis. 2019 Mar 25. doi: 10.1055/s-0039-1679956.
    PubMed     Text format     Abstract available

  45. MAIERS JL, Malhi H
    Endoplasmic Reticulum Stress in Metabolic Liver Diseases and Hepatic Fibrosis.
    Semin Liver Dis. 2019 Mar 25. doi: 10.1055/s-0039-1681032.
    PubMed     Text format     Abstract available

  46. PATTEN DA, Shepherd EL, Weston CJ, Shetty S, et al
    Novel Targets in the Immune Microenvironment of the Hepatic Sinusoids for Treating Liver Diseases.
    Semin Liver Dis. 2019 Mar 25. doi: 10.1055/s-0039-1678727.
    PubMed     Text format     Abstract available

  47. RODRIGUES SG, Cardenas A, Escorsell A, Bosch J, et al
    Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis.
    Semin Liver Dis. 2019 Mar 25. doi: 10.1055/s-0039-1678726.
    PubMed     Text format     Abstract available


    Transplant Proc

  48. ALFANO G, Ventura P, Fontana F, Marcacci M, et al
    Rhodococcus equi Pneumonia in Kidney Transplant Recipient Affected by Acute Intermittent Porphyria: A Case Report.
    Transplant Proc. 2018 Jun 30. pii: S0041-1345(18)30869.
    PubMed     Text format     Abstract available

  49. MAGISTRI P, Marzi L, Guerzoni S, Vandelli M, et al
    Impact of a Multidisciplinary Team on Alcohol Recidivism and Survival After Liver Transplant for Alcoholic Disease.
    Transplant Proc. 2019;51:187-189.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: